drugset / Trial / NCT03255993

The Tolerability and Pharmacokinetics of Multiple Doses of SPH3127 in Chinese Healthy People

NCT03255993 ↗

Phase 1 Completed 24 enrolled Shanghai Pharmaceuticals Holding Co., Ltd
RandomizedParallel-groupDouble-blindTreatment

Summary

This study was a single center, parallel, randomized, double blind, placebo-controlled phase Ib clinical trial to to evaluate the safety and tolerability and pharmacokinetics of SPH3127 tablet in healthy subjects by increasing multiple dosing

Timeline

Start
2017-10-23
Primary completion
2018-09-20
Completion
2018-09-20

Drugs

EvaluationDrugModalityDoseRoute
Subject sitokiren Small molecule 100 mg —
Subject sitokiren Small molecule 200 mg —
Subject sitokiren Small molecule 400 mg —

Indications